The aim of this work was to characterize and exploit a newly developed murine monoclonal antibody specific for the PTPRG extracellular domain (named TPγ B9-2) to better define PTPRG protein downregulation in CML patients. This evidence concerns the gene PTPRG and chronic myelogenous leukemia, BCR-ABL1 positive.